The Role of the Surgeon in Malignant Lymphoma

2015 ◽  
pp. 87-92
Author(s):  
H. de Marliave ◽  
B. Bacle ◽  
J. -F. Dyon ◽  
R. Sarrazin
Keyword(s):  
Malignant Lymphoma

The Role of Splenectomy in Malignant Lymphoma and Leukemia

1967 ◽  
Vol 47 (5) ◽  
pp. 1163-1171 ◽  
Author(s):  
William R. Meeker ◽  
Jose M. dePerio ◽  
James T. Grace ◽  
Leon Stutzman ◽  
Arnold Mittelman
Keyword(s):  
Malignant Lymphoma

scholarly journals IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells

Blood ◽  
2009 ◽  
Vol 114 (2) ◽  
pp. 360-370 ◽  
Author(s):  
Ping Shi ◽  
Raymond Lai ◽  
Quan Lin ◽  
Abid S. Iqbal ◽  
Leah C. Young ◽  
...  
Keyword(s):  
T Cell ◽  
Tyrosine Kinase ◽  
Malignant Lymphoma ◽  
Cell Lines ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Type I ◽  
Large Cell Lymphoma

Abstract Type I insulin-like growth factor receptor (IGF-IR) tyrosine kinase plays important roles in the pathogenesis of several malignancies. Although it promotes the growth of stimulated hematopoietic cells, a direct role of IGF-IR in malignant lymphoma has not been identified. Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+ ALCL) is a unique type of T-cell lymphoma. Approximately 85% of ALK+ ALCL cases harbor the translocation t(2;5)(p23;q35), which generates the chimeric oncogene NPM-ALK. In the present study, we explored a possible role of IGF-IR in ALK+ ALCL. Our results demonstrate that IGF-IR and IGF-I are widely expressed in ALK+ ALCL cell lines and primary tumors. Importantly, we identified novel reciprocal functional interactions between IGF-IR and NPM-ALK. Antagonism of IGF-IR decreased the viability, induced apoptosis and cell-cycle arrest, and decreased proliferation and colony formation of ALK+ ALCL cell lines. These effects could be explained by alterations of cell survival regulatory proteins downstream of IGF-IR signaling. Our findings improve current understanding of the biology of IGF-IR and NPM-ALK and have significant therapeutic implications as they identify IGF-IR signaling as a potential therapeutic target in ALK+ ALCL and possibly other types of malignant lymphoma.

scholarly journals The role of microRNA-150 as a tumor suppressor in malignant lymphoma

Leukemia ◽  
2011 ◽  
Vol 25 (8) ◽  
pp. 1324-1334 ◽  
Author(s):  
A Watanabe ◽  
H Tagawa ◽  
J Yamashita ◽  
K Teshima ◽  
M Nara ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Malignant Lymphoma

scholarly journals Role of micro RNA in the pathogenesis of malignant lymphoma

2013 ◽  
Vol 104 (7) ◽  
pp. 801-809 ◽  
Author(s):  
Hiroyuki Tagawa ◽  
Sho Ikeda ◽  
Kenichi Sawada
Keyword(s):  
Malignant Lymphoma ◽  
Micro Rna

scholarly journals Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C

2005 ◽  
Vol 130 (6) ◽  
pp. 869-877 ◽  
Author(s):  
Ikuko Kadowaki ◽  
Ryo Ichinohasama ◽  
Hideo Harigae ◽  
Kenichi Ishizawa ◽  
Yoko Okitsu ◽  
...  
Keyword(s):  
Malignant Lymphoma

scholarly journals The Role Of Erythropoietin In The Treatment Of Anemia In Patients With Malignant Lymphoma

2013 ◽  
Vol 59 (3) ◽  
pp. 169-171
Author(s):  
Aranka Kurtus ◽  
Erzsébet Benedek ◽  
Judith Beáta Köpeczi ◽  
Enikő Kakucs ◽  
Aliz-Beáta Tunyogi ◽  
...  
Keyword(s):  
Malignant Lymphoma ◽  
Symptom Relief ◽  
Hemoglobin Concentration ◽  
Direct Consequence ◽  
Common Complication ◽  
Malignant Lymphomas ◽  
Acceptable Quality ◽  
Erythropoietin Treatment

Abstract Introduction: Anemia is a common complication of malignant lymphomas, which could be a direct consequence of the disease or secondary to the myelosupressive chemotherapy. The aim of this study was to assess the effect of erythropoietin to treat anemia. The main objectives were to demonstrate increases in hemoglobin levels and the existence of an association between symptom relief and treatment. Material and method: In the Clinical Hematology and BMT Unit Tîrgu Mureș we performed an analytical, observational study to assess the role of erythropoietin treatment in malignant lymphoma related anemia. This linear, retrospective study included 127 patients diagnosed and treated with malignant lymphoma between January 1st, 2007 and December 30, 2011. The 127 patients were divided into two groups: a group of patients (n = 88) who were treated with erythropoietin and the other group (n = 39) who did not receive this treatment. Patients included in the study received treatment with epoetin beta 40,000 IU/week. We followed the hemoglobin level and the symptomatology at baseline and after 4 weeks. Results: Patients who received treatment with erythropoietin had a 7.12 times higher possibility of being asymptomatic than patients who did not receive this treatment. The hemoglobin concentration of patients with erythropoietin treatment increased significantly (p <0.0001) compared to the patients who did not receive this treatment. Conclusion: Effective treatment of anemia is an important aim in the management of patients with malignant lymphomas, because it increases their hemoglobin concentration, decreases the need of transfusion and maintains an acceptable quality of life.

The role of granulopoiesis-stimulating factors in the treatment of malignant lymphoma

2001 ◽  
Vol 1 (S3) ◽  
Author(s):  
Julia Bohlius ◽  
Marcel Reiser ◽  
Andreas Engert
Keyword(s):  
Malignant Lymphoma

Role of PET/CT screening in detecting a second primary carcinoma in patients with malignant lymphoma

2011 ◽  
Vol 90 (12) ◽  
pp. 1485-1486 ◽  
Author(s):  
Reona Sakemura ◽  
Junji Hiraga ◽  
Takahito Okuda ◽  
Shinichi Mizuno
Keyword(s):  
Malignant Lymphoma ◽  
Primary Carcinoma ◽  
Second Primary ◽  
Ct Screening ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document